skip to main | skip to sidebar

Afrezza

AFREZZA™ is a novel, ultra rapid acting mealtime insulin therapy by Mannkind Corporation. Visit Mannkind's official website www.mannkindcorp.com for more information;

  • Site Map
  • Home
  • Afrezza
  • Mannkind
  • Analysts
  • CEO
  • Stock
  • Physicians
  • Patients
  • News
  • Report

Thursday, March 8, 2012

Liang insider trading documents

 

CREW Letter to SEC
Amended Complaint 06 02 2011
CY Liang Insider Trading
Liang Pleads Guilty
SEC Charges 03 29 2011
SEC Complaint 03 29 2011
Shkreli Seeking Alpha 01 19 2012
Liang trades Tracked

Email ThisBlogThis!Share to TwitterShare to Facebook

Newer Post Older Post Home

Search This Blog

Loading...

Interviews with management

  • Interview with Alfred E. Mann - June-2010
  • Al Mann speech at Johns Hopkins - 2010 (new)
  • Al Mann speech at OCR - 2010 (new)
  • Fox news video on inhaled insulin
  • Pete Richardson - Clip syndicate video
  • MannKind's CFO Pfeffer Upbeat on Afresa's Future
  • Interview with Dr Andrea Leone Bay
  • Hakan interview - may 26-2010

MNKD Quick quote

Upcoming events

Afrezza

Completion of pt enrollment in Studies 171 and 174 - 2Q12
Completion of Studies 171 and 174 - YE12
Results of Studies 171 and 174 - Late 2012/1Q13
Re-submission to FDA - 1H13
Potential 3rd PDUFA - 4Q13

Subscribe To Afrezza blog

Posts
Atom
Posts
Comments
Atom
Comments

Blog Archive

  • ►  2013 (7)
    • ►  May (3)
    • ►  March (3)
    • ►  January (1)
  • ▼  2012 (24)
    • ►  November (1)
    • ►  August (1)
    • ►  July (1)
    • ►  May (1)
    • ►  April (1)
    • ▼  March (6)
      • Seduced by Food: Obesity and the Human Brain
      • Needle free technology for Diabetes
      • Liang insider trading documents
      • MannKind at Cowen Group Health Care Conference
      • FDA - A place where politics trumps science
      • Afrezza blog Sitemap
    • ►  February (6)
    • ►  January (7)
  • ►  2011 (34)
    • ►  November (2)
    • ►  October (2)
    • ►  August (5)
    • ►  July (1)
    • ►  June (3)
    • ►  May (5)
    • ►  March (4)
    • ►  February (2)
    • ►  January (10)
  • ►  2010 (124)
    • ►  December (19)
    • ►  November (11)
    • ►  October (12)
    • ►  September (9)
    • ►  August (16)
    • ►  July (8)
    • ►  June (14)
    • ►  May (21)
    • ►  April (3)
    • ►  March (6)
    • ►  February (5)
  • ►  2009 (9)
    • ►  December (9)

Labels

Wells Fargo (13) Rodman (10) HbA1C (8) afrezza (8) Bank of America (7) Al Mann (6) FDA (5) Mannkind (5) Hapoalim (4) Oppenheimer (4) Griffin (3) JP Morgan (3) Leerink (3) Renshaw (3) Research analyst (3) TI (3) CRT (2) Comparison of Exubera and Afresa (2) Diabetologists (2) Early intervention (2) JMP (2) Joshua Schimmer (2) Piper Jaffray (2) Technosphere (2) first phase insulin release (2) hypos (2) titration (2) Approval (1) Baird (1) Comments (1) Cramer (1) Guest contributor (1) Heinemann (1) Morgan Stanley (1) PPG (1) Pulmonary Delivery (1) Real users (1) Shorts (1) Transcripts (1) Valuation (1) eAG (1) earnings conference call summary (1) interview (1)

Links I like

  • KLLJ blog
  • Robert S. Horn Medbio

Yahoo !

Google Mannkind feed

Loading...
 

Mannkind's products

Mannkind's products